临时经静脉膈肌起搏辅助撤机随机试验方案
机械通气可导致膈肌萎缩、损伤及功能障碍(VIDD),使撤机困难并增加患病和死亡风险。本文介绍一项随机、对照、开放标签、多中心试验方案,拟纳入至少88例至少7天内两次自主呼吸试验失败、仍需机械通气的成人患者,按1:1随机接受临时经静脉膈肌起搏(TTVDP)或标准治疗,评估其安全性和有效性。主要疗效终点为成功拔管且48小时内无需再插管的时间;研究假设为TTVDP组在随机化后30天内成功撤机的患者多于对照组。
要点
- TTVDP是首个针对VIDD、旨在加速困难撤机的治疗性技术。
- 主要疗效终点为成功拔管且48小时内无需再插管的时间。
- 研究假设为TTVDP组随机化后30天内成功撤机者多于对照组。
核心结论
- TTVDP有望成为针对VIDD、加速困难撤机的新型治疗,其临床定位有待本试验结果界定。
研究设计与样本
- 随机、对照、开放标签、多中心试验方案,拟纳入最多88例仍机械通气的成人患者,按1:1随机分为TTVDP组与标准治疗组。
- 纳入患者需在至少7天内至少两次自主呼吸试验失败。
- 试验注册号ClinicalTrials.gov NCT03096639,注册日期2017年3月30日。
主要发现
- 主要疗效终点为成功拔管且48小时内无需再插管的时间。
- 次要终点包括最大吸气压及超声测量的膈肌厚度与膈肌增厚分数随时间的变化。
- 另收集并分析观察性数据,包括30天死亡率及重症监护病房和医院出院时间。
关键数值与推荐
- 研究假设:TTVDP组在随机化后30天内成功撤机的患者多于对照组。
- 主要终点为成功拔管且48小时内无需再插管的时长。
临床怎么用
- 该方案为TTVDP的临床定位与后续研究设计提供依据,尚待试验结果明确其适应证与获益。
局限性
- 本文为试验方案,尚无疗效与安全性结果报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mechanical ventilation (MV) is a life-saving technology that restores or assists breathing. Like any treatment, MV has side effects. In some patients it can cause diaphragmatic atrophy, injury, and dysfunction (ventilator-induced diaphragmatic dysfunction, VIDD). Accumulating evidence suggests that VIDD makes weaning from MV difficult, which involves increased morbidity and mortality. METHODS AND ANALYSIS: This paper describes the protocol of a randomized, controlled, open-label, multicenter trial that is designed to investigate the safety and effectiveness of a novel therapy, temporary transvenous diaphragm pacing (TTVDP), to improve weaning from MV in up to 88 mechanically ventilated adult patients who have failed at least two spontaneous breathing trials over at least 7 days. Patients will be randomized (1:1) to TTVDP (treatment) or standard of care (control) groups. The primary efficacy endpoint is time to successful extubation with no reintubation within 48 h. Secondary endpoints include maximal inspiratory pressure and ultrasound-measured changes in diaphragm thickness and diaphragm thickening fraction over time. In addition, observational data will be collected and analyzed, including 30-day mortality and time to discharge from the intensive care unit and from the hospital. The hypothesis to be tested postulates that more TTVDP patients than control patients will be successfully weaned from MV within the 30 days following randomization. DISCUSSION: This study is the first large-scale clinical trial of a novel technology (TTVDP) aimed at accelerating difficult weaning from MV. The technology tested provides the first therapy directed specifically at VIDD, an important cause of delayed weaning from MV. Its results will help delineate the place of this therapeutic approach in clinical practice and help design future studies aimed at defining the indications and benefits of TTVDP. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03096639 . Registered on 30 March 2017.
引用
- Evans D, Shure D, Clark L, et al. Temporary transvenous diaphragm pacing vs. standard of care for weaning from mechanical ventilation: study protocol for a randomized trial. Trials. 2019. PMID: 30654837. doi:10.1186/s13063-018-3171-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。